In 1982 was an epidemic of HIV in San Francisco. 300 patients acquired HIV infections from blood transfusions. The patients did not blame the hospital, but simply asked “Do something about it”. This request became the personal motivation of M.D. Larry Corash to found Cerus.
Chief Medical Officer Richard J. Benjamin MBChB, PhD, FRCPath as well confirmed “The truth is that there is a risk of emerging infectious diseases”, which was part of his motivation to join Cerus. Over the years Cerus has optimized the technologies for Plasma and Platelets, and aims at completing the development programme for Red-Cells. We aspire to become the standard of care and can continue to focus on what is best for patients.
To share this vision and motivation we created this video.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.